Adtalem's FY25 Revenue Jumps 12.9% to $1.79B, EPS Up 33.1%

Ticker: CVSA · Form: DEF 14A · Filed: 2025-10-02T00:00:00.000Z

Sentiment: bullish

Topics: Healthcare Education, Workforce Development, Enrollment Growth, Financial Performance, Higher Education, Strategic Growth, Investor Relations

Related Tickers: CVSA

TL;DR

**CVSA is a buy; their 'Growth with Purpose' strategy is clearly paying off, making them a critical player in the booming healthcare education market.**

AI Summary

Adtalem Global Education Inc. (CVSA) reported robust financial performance for fiscal year 2025, with revenue reaching $1.79 billion, marking a significant 12.9% growth, more than doubling its 2023 investor day targets. Adjusted earnings per share (EPS) surged by 33.1% to $6.67. The company's 'Growth with Purpose' strategy proved effective, driving total enrollment past 91,000 students with over 10% average quarterly growth. Chamberlain University achieved its tenth consecutive quarter of growth, exceeding 40,000 students, while Walden University surpassed 48,000 students, returning to pre-pandemic levels. The Medical and Veterinary segment maintained excellence with over 5,000 enrolled students. Adtalem graduated 29,000 students, with 90% entering healthcare professions, addressing critical workforce shortages. The company is strategically positioning itself as a vital component of U.S. healthcare infrastructure, emphasizing its role in talent pipeline development and accessible, career-focused education.

Why It Matters

Adtalem's strong financial performance and strategic focus on healthcare education directly address critical U.S. workforce shortages, particularly in underserved communities, making it a key player in national healthcare infrastructure. For investors, this signals sustained growth potential and a resilient business model in a high-demand sector, potentially outperforming competitors reliant on traditional higher education models. Employees benefit from a stable, growing company with a clear mission, while customers (students) gain access to career-focused education with high placement rates. The broader market benefits from a more robust healthcare workforce, reducing strain on existing systems.

Risk Assessment

Risk Level: low — The company demonstrated strong operational excellence with 12.9% revenue growth to $1.79 billion and 33.1% adjusted EPS growth to $6.67 in fiscal year 2025. Total enrollment surpassed 91,000 students with over 10% average quarterly growth, indicating robust demand and successful execution of its 'Growth with Purpose' strategy.

Analyst Insight

Investors should consider initiating or increasing positions in CVSA, given its strong financial performance and strategic positioning within the high-demand healthcare education sector. The company's consistent enrollment growth and focus on addressing critical workforce shortages suggest a durable competitive advantage and future growth potential.

Financial Highlights

revenue
$1.79B
eps
$6.67
revenue Growth
+12.9%

Executive Compensation

NameTitleTotal Compensation
Steve BeardCEO
Other NEOsNamed Executive Officers

Key Numbers

Key Players & Entities

FAQ

What were Adtalem Global Education Inc.'s key financial results for fiscal year 2025?

Adtalem Global Education Inc. reported revenue of $1.79 billion for fiscal year 2025, representing a 12.9% increase. Adjusted earnings per share (EPS) grew by 33.1% to $6.67, significantly exceeding previous targets.

How has Adtalem Global Education Inc.'s enrollment changed in fiscal year 2025?

Total enrollment for Adtalem Global Education Inc. surpassed 91,000 students in fiscal year 2025, demonstrating an average quarterly growth of over 10%. Chamberlain University alone reached over 40,000 students, marking its tenth consecutive quarter of growth.

What is Adtalem Global Education Inc.'s strategic outlook for its role in healthcare?

Adtalem Global Education Inc. aims to expand its role as a critical component of America's healthcare infrastructure, becoming a systemically important partner for healthcare employers and policymakers. The company focuses on addressing acute workforce shortages by preparing practice-ready professionals.

Who is the Chairman and CEO of Adtalem Global Education Inc. and what was their message?

Steve Beard is the Chairman and CEO of Adtalem Global Education Inc. In his message, he highlighted fiscal 2025 as a 'proof point and an inflection point,' validating the 'Growth with Purpose' strategy and positioning the company for its next phase of growth.

What are the key proposals for the Adtalem Global Education Inc. Annual Meeting on November 12, 2025?

Shareholders will vote on three key proposals: the election of ten director nominees, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory vote to approve the compensation of named executive officers.

How does Adtalem Global Education Inc. contribute to alleviating healthcare workforce shortages?

Adtalem Global Education Inc. contributes by graduating 29,000 students in fiscal year 2025, with 90% entering healthcare professions. These graduates serve in critical roles in underserved rural communities and urban centers, directly addressing the national healthcare workforce deficit.

What is Adtalem Global Education Inc.'s approach to corporate governance?

Adtalem Global Education Inc. emphasizes strong corporate governance with 80% independent directors, an average board tenure of 6.4 years, and an average age of 61.5 years. The board conducts regular shareholder engagement and has implemented ongoing enhancements like annual strategy meetings and updated stock ownership guidelines.

How is executive compensation structured at Adtalem Global Education Inc.?

Executive compensation at Adtalem Global Education Inc. is strongly linked to individual, institutional, and financial performance. It includes base salary, an annual Management Incentive Plan (MIP) based on revenue and adjusted EPS, and long-term incentives (LTI) comprising RSUs and Performance Share Units (PSUs) tied to revenue growth and adjusted EBITDA margin.

What institutions are part of Adtalem Global Education Inc.?

Adtalem Global Education Inc. is the parent organization for five institutions: American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine, and Walden University.

What is the record date for voting at Adtalem Global Education Inc.'s 2025 Annual Meeting?

The record date for shareholders to be eligible to vote at Adtalem Global Education Inc.'s 2025 Annual Meeting is September 23, 2025. Shareholders as of this date will receive proxy materials and voting instructions.

Risk Factors

Industry Context

Adtalem operates within the competitive higher education sector, with a focus on healthcare and professional education. The industry is characterized by increasing demand for skilled healthcare professionals, driving enrollment in specialized programs. However, it also faces challenges related to regulatory oversight, student financing, and the need for continuous adaptation to technological advancements and evolving workforce needs.

Regulatory Implications

Adtalem's operations are subject to significant regulatory oversight from bodies like the Department of Education and accrediting agencies. Compliance with evolving regulations regarding student aid, program quality, and institutional performance is critical. Non-compliance can lead to penalties, loss of accreditation, and impact student enrollment and financial aid eligibility.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]

Glossary

NEOs
Named Executive Officers, typically the highest-paid executives of a company whose compensation is disclosed in regulatory filings. (The compensation of Adtalem's NEOs is detailed in the proxy statement, including their salary, incentives, and long-term equity awards.)
MIP
Management Incentive Plan, a short-term incentive program designed to reward executives for achieving specific operational and financial goals within a fiscal year. (Adtalem's MIP is a key component of executive compensation, with payouts tied to performance measures like revenue and adjusted EPS.)
RSUs
Restricted Stock Units, a form of equity compensation that grants employees shares of company stock after a vesting period, aligning their interests with shareholders. (RSUs represent a significant portion of Adtalem's long-term incentive compensation for executives, vesting over three years.)
PSUs
Performance Share Units, equity awards where the number of shares ultimately received depends on the achievement of specific performance targets over a defined period. (Adtalem uses Revenue Growth PSUs and Adjusted EBITDA Margin PSUs as part of its long-term executive compensation to drive multi-year financial goals.)
Adjusted EPS
Adjusted Earnings Per Share, a non-GAAP measure that excludes certain items from reported EPS to provide a clearer view of the company's core operating performance. (Adjusted EPS is a key performance metric used in Adtalem's Management Incentive Plan and for assessing overall financial health.)
Adjusted EBITDA Margin
A non-GAAP financial metric representing earnings before interest, taxes, depreciation, and amortization, adjusted for certain items, as a percentage of revenue. (This metric is used as a performance target for Adtalem's long-term incentive equity awards, focusing on profitability relative to revenue.)

Year-Over-Year Comparison

The provided text focuses on the current fiscal year (FY25) and does not contain comparative data from a previous filing. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or new risks versus the prior year cannot be made based on this excerpt. The initial summary indicates significant revenue growth of 12.9% and EPS growth of 33.1%, suggesting a positive performance trajectory compared to the previous year.

Filing Stats: 4,278 words · 17 min read · ~14 pages · Grade level 14.2 · Accepted 2025-10-02 16:15:47

Key Financial Figures

Filing Documents

EXECUTIVE COMPENSATION HIGHLIGHTS

EXECUTIVE COMPENSATION HIGHLIGHTS Strong linkage of pay to individual, institutional, and financial performance Balanced compensation program aligning performance to interests of shareholders, students, and other stakeholders Our Compensation Framework 2025 COMPENSATION SNAPSHOT Objective Time Horizon Performance Measures Additional Explanation Salary (cash) Base Salary Reflect experience, market competition and scope of responsibilities Reviewed Annually Assessment of performance in prior year. Represents 6% and 33% (on average) of target Total Direct Compensation for Mr. Beard and other NEOs, respectively. Annual Incentive (cash) Management Incentive Plan ("MIP") Reward achievement of short-term operational business priorities 1 year Revenue* Adjusted earnings per share ("EPS")* Individual performance modifier Represents 8% and 25% (on average) of target Total Direct Compensation for Mr. Beard and other NEOs respectively. Long-Term Incentive (equity) RSUs Align interests of management and shareholders, and retain key talent 3 year ratable vest Stock price growth Represents 40% of NEO regular annual LTI granted in FY25.** Revenue Growth PSUs Reward achievement of multi-year financial goals, align interests of management and shareholders, and retain key talent 3 year cliff vest Revenue Growth Represents 30% of NEO regular annual LTI granted in FY25.** Adjusted EBITDA Margin PSUs Adjusted EBITDA margin Represents 30% of NEO regular annual LTI granted in FY25.** * The MIP payout for executive leadership of the institutions is based on revenue and adjusted operating income at such executive's institution(s). ** The total regular annual long-term incentive ("LTI") award consisting of both RSUs and Performance Share Units (PSUs) represents 86% of target Total Direct Compensation for Mr. Beard and 41% of target Total Direct Compensation for other NEOs (on average), respectively. Adtalem Global Education

Executive Compensation Highlights

Executive Compensation Highlights 11 PROPOSAL NO. 1 ELECTION OF DIRECTORS 12 Board Composition 19 Director Nominating Process 19 Board Succession Planning 22 Board Structure and Operations 25 Key Board Responsibilities 28 Board Practices and Policies 29 Director Compensation 31 PROPOSAL NO. 2 RATIFY SELECTION OF PRICEWATERHOUSECOOPERS LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 31 Selection and Engagement of Independent Registered Public Accounting Firm 31 Pre-Approval Policies 32 Audit Fees and Other Fees 33 Audit and Finance Committee Report 34 PROPOSAL NO. 3 SAY-ON-PAY: ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS ("NEOs") 34 Compensation Discussion & Analysis Roadmap 63 Section 6: Compensation Committee Report 64

EXECUTIVE COMPENSATION TABLES

EXECUTIVE COMPENSATION TABLES 64 2025 Summary Compensation Table 65 2025 Grants of Plan-Based Awards 66 2025 Outstanding Equity Awards at Fiscal Year-End 67 2025 Options Exercises and Stock Vested 68 2025 Nonqualified Deferred Compensation 69 Nonqualified Deferred Compensation Plan 69 2025 Potential Payments Upon Termination or Change-In-Control 71 CEO Pay Ratio 72 P ay Versus Performance 76 Equity Compensation Plan Information 77 VOTING SECURITIES AND PRINCIPAL HOLDERS 77

Security Ownership of Certain Beneficial Owners

Security Ownership of Certain Beneficial Owners 78

Security Ownership by Directors and Executive Officers

Security Ownership by Directors and Executive Officers 79 ADDITIONAL INFORMATION 79 Voting Instructions 81 Voting Information 82 Proxy Solicitation 82 Shareholder Proposals for 2026 Annual Meeting 82 Availability of Form 10-K 82 Householding 82 Proxy Materials are Available on the Internet 83 Delinquent Section 16(a) Reports 83 Other Business A- 1 APPENDIX A – RECONCILIATION OF NON-GAAP FINANCIAL MEASURES USED IN COMPENSATION PERFORMANCE ASSESSMENTS TO COMPARABLE MEASURES 10 2025 Proxy Statement Adtalem Global Education Inc. Table of Contents PROPOSAL NO. 1 Election of Directors The Board has nominated each of Adtalem's ten incumbent directors and recommends their re-election, each for a term to expire at the 2026 Annual Meeting. All of the nominees have consented to serve as directors if elected at the Annual Meeting. It is intended that all shares represented by proxy at the Annual Meeting will be voted for the election of each of Stephen W. Beard, William W. Burke, Donna J. Hrinak, Georgette Kiser, Liam Krehbiel, Michael W. Malafronte, Sharon L. O'Keefe, Kenneth J. Phelan, Betty Vandenbosch, and Lisa W. Wardell as directors unless otherwise specified in such proxy. A proxy cannot be voted for more than ten persons. If a nominee becomes unable to serve as a director, the proxy committee (appointed by the Board) will vote for the substitute nominee that the Board designates. The Board has no reason to believe that any of the nominees will become unavailable for election. Each nominee for election as a director is listed below, along with a brief statement of his or her current or most recent principal occupation, business experience, and other information, including directorships in other public companies held as of the date of this Proxy Statement or within the previous five years. Under the heading "Reasons for Nomination," we describe briefly the particular experience, qualifications, attributes, or skill

View on Read The Filing